Journal: Journal of Hepatocellular Carcinoma
Article Title: GRB2 Promotes Sorafenib Resistance in Hepatocellular Carcinoma Cells Under Hypoxia by Activating the PI3K/AKT Signaling Pathway
doi: 10.2147/JHC.S581550
Figure Lengend Snippet: Down-regulation of GRB2 suppressed PI3K/AKT pathway in HCC cells. ( A ) GRB2 knockdown efficiency verified by Western blotting and RT-qPCR in stable cell lines; ( B ) CCK-8 viability (sorafenib 0,5,10,15,20 μM, hypoxia, 24 h) in shGRB2-NC, shGRB2-1, shGRB2-2; ( C ) Wound healing (sorafenib 5 μM, hypoxia, 24 h); ( D ) Flow cytometry (sorafenib 5 μM, hypoxia, 24 h); ( E ) Western blotting of GRB2, PI3K, AKT, p-AKT (sorafenib 5 μM, hypoxia, 24 h). The data presented here are based on three independent experiments. “*” indicates P < 0.05, “**” P < 0.01, “***” P < 0.001.
Article Snippet: Lentiviral particles carrying shRNA targeting GRB2 (shGRB2-1: CAGATATTCCTGCGGGACATA, shGRB2-2: CGGCTTCATTCCCAAGAACTA) and negative control (shGRB2-NC: TTCTCCGAACGTGTCACGT) were constructed by GeneChem (Shanghai, China).
Techniques: Knockdown, Western Blot, Quantitative RT-PCR, Stable Transfection, CCK-8 Assay, Flow Cytometry